Fig. 5.

Suppression of tumor treatment effect due to STING deficiency. In the in vivo experiments, C57BL/6 (wild-type; WT) mice and STING KO (knockout) mice were used. a Schedule flowchart. b Tumor mass was measured until the mice died or the tumor diameter was > 2 cm (n = 5). c Mouse survival observed after 60 days (n = 5). d One week after the last vaccination, the tumor tissues and spleens of TC-1 tumor-bearing mice were harvested and re-stimulated with E7 short peptide and then analyzed for IFN-γ⁺ CD8⁺ T cells by flow cytometry (n = 5). e Bar graphs depicting the in vitro expression of PD-L1 in TC-1 tumor cells determined by flow cytometry. BMDCs and pDCs isolated and differentiated from C57BL/6 and STING KO mice were treated with or without 10 μg/ml DMXAA and the supernatant was treated with TC-1 cells overnight. IBM SPSS Statistics Base 22.0 was used for statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001